MOTS-c
Also known as Mitochondrial Open Reading Frame of 12S rRNA type-c
A 16-amino-acid peptide encoded in mitochondrial DNA that improves insulin sensitivity and cellular energy output.
Definition
MOTS-c functions as a mitokine signaling from mitochondria. It activates AMPK, enhances insulin sensitivity, and improves glucose and fatty-acid metabolism. Research indicates protection against age-related insulin resistance and obesity.
How Meto uses it.
Included in the SCULPT body-composition protocol alongside Tesamorelin; not currently available while awaiting FDA regulatory action. Dosing: 10 mg subcutaneous once or twice weekly across 12-week cycles. Pairs effectively with GLP-1 therapy for members with plateau fat loss and residual insulin resistance.
Safety notes
- Human clinical evidence is early — most data is preclinical
- Avoid in pregnancy and lactation
- No documented significant drug-drug interactions
Not a complete list — your clinician reviews your full history, labs and medications during intake. Nothing here replaces that.
Common questions
Efficacy in humans
Human data remains limited; preclinical research supports mechanism but RCT evidence lags behind GLP-1 standards.
Dosing frequency
Extended biological effect justifies weekly/twice-weekly dosing rather than daily.
Read More
AMPKAMP-Activated Protein Kinase
The cellular energy sensor that triggers fat burning, glucose uptake and mitochondrial biogenesis when ATP runs low — activated by MOTS-c.
Clinical ConceptMitochondria
The cellular organelles that produce ATP — the direct target of NAD+ supplementation and mitochondrial peptides like MOTS-c.
Clinical ConceptInsulin Sensitivity
How effectively cells respond to insulin — improved by exercise, GLP-1s, MOTS-c and most metabolic peptides.
$149 panel.
A clinician reads it in 24 hours.
Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.